Trials for neurodegenerative diseases: time to innovate

TY - JOUR

T1 - Trials for neurodegenerative diseases

T2 - time to innovate

AU - Mehta, Arpan R

AU - Chataway, Jeremy

AU - Pal, Suvankar

AU - Parmar, Mahesh K B

AU - Chandran, Siddharthan

PY - 2021/12

Y1 - 2021/12

N2 - The remarkable progress in our understanding of the mechanisms underlying neurodegenerative diseases heralds an era when neurologists would be at the vanguard of regenerative medicine, instead of chroniclers of decline. To capitalise on these advances that are identifying ever more therapeutic candidates, whether repurposed or entirely new, there is an urgent need for refined methods to test these putative medicines in clinical trials. Our field has the opportunity to learn from innovations in trial design, particularly those pioneered in oncology.

AB - The remarkable progress in our understanding of the mechanisms underlying neurodegenerative diseases heralds an era when neurologists would be at the vanguard of regenerative medicine, instead of chroniclers of decline. To capitalise on these advances that are identifying ever more therapeutic candidates, whether repurposed or entirely new, there is an urgent need for refined methods to test these putative medicines in clinical trials. Our field has the opportunity to learn from innovations in trial design, particularly those pioneered in oncology.

UR - https://www.scopus.com/pages/publications/85119273910

U2 - 10.1016/S1474-4422(21)00388-4

DO - 10.1016/S1474-4422(21)00388-4

M3 - Article

C2 - 34800413

SN - 1474-4422

VL - 20

SP - 984

JO - Lancet Neurology

JF - Lancet Neurology

IS - 12

ER -